Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | FEMASYS INC - 8-K, Current Report | 4 | SEC Filings | ||
03.07. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
26.06. | Femasys-Aktie steigt nach CE-Kennzeichnung für FemBloc zur dauerhaften Empfängnisverhütung | 2 | Investing.com Deutsch | ||
FEMASYS Aktie jetzt für 0€ handeln | |||||
26.06. | Femasys stock rises as FemBloc gets CE Mark for permanent birth control | 1 | Investing.com | ||
25.06. | FEMASYS INC - 8-K, Current Report | - | SEC Filings | ||
25.06. | Femasys Inc.: Femasys Announces Historic Milestone with European Approval of FemBloc, the First Non-Surgical Permanent Birth Control | 195 | GlobeNewswire (Europe) | ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive... ► Artikel lesen | |
17.06. | Femasys appoints Kelley Nicholas as chief commercial officer | 1 | Investing.com | ||
17.06. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
11.06. | The Analyst Verdict: Femasys In The Eyes Of 6 Experts | 2 | Benzinga.com | ||
11.06. | Femasys Inc.: Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed in its More than 8 Locations | 1 | GlobeNewswire (USA) | ||
02.06. | FEMASYS INC - 8-K, Current Report | - | SEC Filings | ||
30.05. | Femasys Announces $4.5 Mln Offering Through Public Sale And Private Placement Of Shares | 1 | RTTNews | ||
30.05. | Femasys announces pricing of underwritten public offering and concurrent private placement with gross proceeds of $4.5M | 2 | Seeking Alpha | ||
30.05. | Femasys Inc.: Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million | 3 | GlobeNewswire (USA) | ||
29.05. | Femasys plans stock offering and private placement | 1 | Investing.com | ||
29.05. | Femasys announces public offering, concurrent private placement | 1 | Seeking Alpha | ||
29.05. | Femasys plant Aktienangebot und Privatplatzierung | 2 | Investing.com Deutsch | ||
29.05. | Femasys Inc.: Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement | 1 | GlobeNewswire (USA) | ||
23.05. | Femasys droht Delisting von der NASDAQ | 1 | Investing.com Deutsch | ||
23.05. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
INTUITIVE SURGICAL | 426,35 | -0,01 % | Opening Bell: Block, Alphabet, Tesla, NextEra Energy, Intuitive Surgical, Constellation Energy | Nachdem die US-Börsen am Freitag zunächst knapp neue Rekordstände erreicht hatten, gaben die Kurse im weiteren Verlauf nach und schlossen weitgehend unverändert. Sowohl der S&P 500 als auch die Nasdaq... ► Artikel lesen | |
UNITEDHEALTH | 248,25 | -0,10 % | Want To Bet Bigger On UnitedHealth? Now There's A Cheaper Way | ||
THERMO FISHER | 398,30 | +0,49 % | Thermo Fisher Scientific-Aktie mit großen Kursgewinnen (403,70 €) | Im US-amerikanischen Wertpapierhandel brilliert zur Stunde die Thermo Fisher Scientific-Aktie . Der Titel steigt deutlich. Eine Steigerung um 11,03 Prozent - mit diesem Preisanstieg gehört der Anteilsschein... ► Artikel lesen | |
ROKU | 76,51 | -0,20 % | I changed 6 settings on my Roku TV to instantly improve the performance | ||
ATOSSA THERAPEUTICS | 0,765 | +1,46 % | Atossa Therapeutics, Inc.: Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 | SEATTLE, WASHINGTON / ACCESS Newswire / May 20, 2025 / Atossa Therapeutics, Inc. (Nasdaq:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines... ► Artikel lesen | |
EVOFEM BIOSCIENCES | - | - | 'We want to be different than pharma': Evofem CEO on the TikTok that tripled interest in Phexxi birth control | ||
CENTENE | 24,860 | -0,54 % | Centene-Aktie verliert 4,01 Prozent (25,1966 €) | Am US-amerikanischen Aktienmarkt liegt der Anteilsschein von Centene gegenwärtig im Minus. Der jüngste Kurs betrug 29,19 US-Dollar. An der Börse liegt der Anteilsschein von Centene derzeit im Minus.... ► Artikel lesen | |
VERU | 0,519 | +3,88 % | Veru Inc.: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation | --During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study... ► Artikel lesen | |
QUIDELORTHO | 21,800 | -3,54 % | QuidelOrtho Corporation: QuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs | New executives bring deep expertise to elevate quality and accelerate innovation across global operations SAN DIEGO, July 7, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL)... ► Artikel lesen | |
TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China | Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest... ► Artikel lesen | |
NANO-X IMAGING | 5,455 | 0,00 % | Nano-X Imaging LTD.: Nanox Announces Clinical and Educational Collaboration with Keiser University Featuring the Nanox.ARC | Nanox.ARC delivers advanced 3D imaging with proprietary cold cathode technologyClinical studies show superior diagnostic performance to X-ray with reduced radiation exposure compared to CT PETACH... ► Artikel lesen | |
FULGENT GENETICS | 16,100 | 0,00 % | Fulgent Genetics gets EU approval for germline sequencing system | ||
LANTHEUS | 62,32 | +0,10 % | Lantheus Holdings, Inc.: Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D | BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), today announced the successful completion of its previously disclosed acquisition... ► Artikel lesen | |
PERSPECTIVE THERAPEUTICS | 3,740 | +1,63 % | Perspective Therapeutics, Inc.: Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results | SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers... ► Artikel lesen | |
AMN HEALTHCARE SERVICES | 16,000 | -8,57 % | Truist Securities bestätigt Kaufempfehlung für AMN Healthcare und sieht Potenzial im internationalen Pflegesektor/n |